Targeting negative regulators of MAPK signaling inhibitors such as DUSP4 and PEA15 further activates MAPK signaling and may therefore be particularly effective in eliminating melanoma cells that have acquired resistance to BRAF and MEK inhibition. The gene discussed is BRAF; the disease is melanoma.